Cargando…
Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline
Clinical responses to standard cytarabine plus anthracycline regimen in acute myeloid leukemia (AML) are heterogeneous and there is an unmet need for biological predictors of response to this regimen. Here, we applied a pharmacometabolomics approach to identify potential biomarkers associated with r...
Autores principales: | Tan, Guangguo, Zhao, Bingbing, Li, Yanqing, Liu, Xi, Zou, Zhilan, Wan, Jun, Yao, Ye, Xiong, Hong, Wang, Yanyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687638/ https://www.ncbi.nlm.nih.gov/pubmed/29179468 http://dx.doi.org/10.18632/oncotarget.20733 |
Ejemplares similares
-
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019) -
Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia
por: Yan, Han, et al.
Publicado: (2016) -
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021) -
O,O′-Di-p-tolylpyrophosphoric bis(dimethylamide)
por: Pourayoubi, Mehrdad, et al.
Publicado: (2010) -
Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)